Plainsboro, NJ, October 19, 2015 -- The nation’s leading digital and print resource for oncology professionals, OncLive®, announced today it is doubling the frequency of its flagship publication, OncologyLive, to keep pace with the quickly evolving oncology marketplace. Starting in January, the clinical news publication will publish twice a month, with expanded coverage of emerging therapeutic strategies and research developments.
“We are proud to announce the expansion of the premier publication for busy practicing oncologists and hematologists,” said Mike Hennessy Jr., president of the Oncology and Healthcare Specialty Group of Intellisphere, LLC, publisher of OncologyLive. “Expanding the publication schedule will help oncology specialists in daily clinical practice stay abreast of the wealth of new developments in the field and better serve their patients.”
The new bi-monthly publishing schedule will allow OncologyLive to provide even more timely and dynamic reports about research presented at oncology conferences, FDA actions, including new drug approvals, and peer-reviewed advances in clinical practice. With the more aggressive schedule, there will be even more extensive coverage of major oncology meetings held in the United States and internationally, along with additional in-depth articles that feature the insights of the world-renowned oncologists who participate in Physicians’ Education Resource meetings.
“OncologyLive will increasingly become the GO TO publication for practicing oncologists and others looking for critical updates and information relevant to the care of patients with malignant disease,” said Maurie Markman, M.D., editor-in-chief of OncologyLive. Markman is also president of Medicine & Science for Cancer Treatment Centers of America.
The unique and robust mix of information that OncologyLive offers includes OncLive Peer Exchange articles based on the website’s video roundtables that feature leading experts in particular tumor types discussing the latest developments. Its OncPathways series examines the newest findings about cell-signaling networks, and the Precision Medicine in Oncology section focuses on a wide range of emerging diagnostics.
Each issue also will feature articles written by faculty members from prominent cancer centers through the OncLive Strategic Alliance Partnership program, which encompasses nearly 60 oncology care institutions. Profiles of Giants of Cancer Care® award winners will continue to appear in an expanded People in the News section that also will spotlight recent appointments, promotions and awards given to academic and community oncology specialists. OncologyLive is mailed to more than 22,000 oncology specialists, including medical oncologists, hematologists, radiation oncologists, urologists, gynecologic oncologists and head and neck surgeons.
OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News, Contemporary Oncology and Contemporary Radiation Oncology. OncLive offers oncology professionals resources and information they need to provide the best care for their patients. Intellisphere, LLC, a leading provider of healthcare publishing, research and education, is part of the Michael J. Hennessy Associates, Inc. (MJH) family of businesses, based in Plainsboro, NJ. MJH also includes the acclaimed CURE Media Group, which combines science and humanity to make cancer understandable. Its flagship product is CURE® magazine, the largest consumer publication in the U.S. focused entirely on cancer, reaching cancer patients, cancer centers and advocacy groups. To learn more, please visit http://www.OncLive.com.
For OncLive: Becky Taylor, 609-240-6886, becky(at)btaylorpa(dot)com
|Title||Expiration Date||CME Credits|
|Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut Allergy||Sep 28, 2019||1.0|
|Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video Update||Sep 28, 2019||2.0|